News and Trends 9 Jan 2023Alentis reports positive results from fibrosis study Alentis Therapeutics has announced positive results from a single ascending dose phase 1 study of its lead program, ALE.F02, currently… January 9, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 11 Oct 2022First patient dosed in study of idiopathic pulmonary fibrosis Redx, a clinical-stage biotech company, is trialing RXC007, a wholly owned rho associated coiled-coil containing protein kinase 2 (ROCK2) selective… October 11, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email